COMMUNIQUÉS West-GlobeNewswire

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
26/03/2025
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e – - Both groups demonstrated [...]
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
26/03/2025
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year [...]
Dyadic Reports 2024 Year-End Financial Results and Business Updates
26/03/2025
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 [...]
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
26/03/2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
CRISPR Therapeutics Announces Transition of Chief Operating Officer
26/03/2025
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
26/03/2025
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases Initial data for NKX019 in multiple autoimmune indications [...]
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
26/03/2025
FDA Approval of Emrosi™ ( 40 mg Minocycline Hydrochloride Modified-Release Capsules ) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 [...]
Inventiva reports its 2024 full year results and provides a business update
26/03/2025
Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 [...]
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
26/03/2025
Chiffre d'affaires de 9,2 millions d'euros pour l’année 2024 Trésorerie et équivalents de trésorerie à 96,6 millions d’euros au 31 décembre 2024 Levée d’un produit brut de 116 millions d’euros dans le cadre de la [...]
Heartflow Closes $98 Million Convertible Notes Financing
26/03/2025
Additional Capital to Support Broadening Adoption of a Leading Platform That Transforms Diagnosis and Management of Coronary Artery Disease MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. , the [...]
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
26/03/2025
WARREN, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug [...]
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
26/03/2025
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
26/03/2025
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million 1 as of December 31, 2024, ensuring financial visibility until Q1 [...]
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement
26/03/2025
OSE Immunotherapeutics publie ses résultats financiers annuels 2024 et fait le point sur sa stratégie de développement Revenu total de 83,4 millions d’euros et position de trésorerie 1 de 64,2 millions d’euros au 31 [...]
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
26/03/2025
Saint-Herblain (France), March 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part [...]
Valneva renouvelle son contrat de placement (Sales Agreement) dans le cadre de son programme « At-the-Market (ATM) » existant
26/03/2025
Saint-Herblain (France), 26 mars 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce aujourd’hui qu’elle a déposé auprès de la U.S. [...]
GUERBET : Résultats annuels 2024.
26/03/2025
Résultats annuels 2024 Activité très dynamique Chiffre d’affaires annuel : 841,1 M€, affichant une progression de 9,0% à taux de change constant (TCC) 1 et périmètre comparable 2 Une dynamique soutenue dans la zone [...]
GUERBET : 2024 full-year results.
26/03/2025
2024 full-year results Very strong business momentum Full-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER) 1 and on a like-for-like basis 2 Strong momentum in the Americas (+20.5% at CER and like- [...]
Trading by management and close relations of management
26/03/2025
Please read the full announcement in PDF Attachment 2025_14_Trading_By_Management

Pages